Search

Your search keyword '"Planchamp, François"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Planchamp, François" Remove constraint Author: "Planchamp, François"
65 results on '"Planchamp, François"'

Search Results

51. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas.

52. ESGE/ESGO/SERGS consensus statement on surgical steps in minimally invasive surgery in gynecologic oncology: transperitoneal and extraperitioneal approach for paraaortic lymphadenectomy.

53. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023.

54. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma .

55. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

56. [Management of the nodal disease in vulvar cancers. The ESGO guidelines].

57. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

58. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.

59. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

60. [Surgical management of ovarian cancer: Trends in clinical practice].

61. [Loco-regional treatments of the metastatic sites for patients with pauci-metastatic cutaneous melanoma (without brain metastasis): French national guidelines].

62. [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)].

63. [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers].

64. [Recommendations for clinical practice: use of TEP-FDG in cancer of the esophagus, stomach, colon and rectum, anal canal, large intestine, pancreas and bile ducts, liver and endocrine tumors (digestive system)].

65. [Recommendation for clinical practice: use of PET-FDG in cancer of the kidney, prostate, testicles, and the urinary bladder].

Catalog

Books, media, physical & digital resources